Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in
infants and it also induces significant disease in the elderly. The clinical course may be …

Introduction: Human respiratory syncytial virus (RSV) is a major health threat both for the
very young and the elderly. With yearly 3.2 million hospital admissions and approximately …

Although RSV has been a high priority for vaccine development, efforts to develop a safe
and effective vaccine have yet to lead to a licensed product. Clinical and epidemiologic …

Objective: To explore whether RSV vaccines are efficacious in preventing respiratory
syncytial virus (RSV) lower respiratory infection (LRI). Methods: Randomized clinical trials …

Objective The high burden associated with respiratory syncytial virus (RSV) has made the
development of RSV vaccine (s) a global health high priority. This review summarizes the …

Respiratory syncytial virus (RSV) is a globally prevalent cause of lower respiratory infection
in neonates and infants. Despite its disease burden, a safe and effective RSV vaccine has …

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract viral disease
in infants and young children. Presently, there are no explicit recommendations for RSV …

The development of an effective vaccine against respiratory syncytial virus (RSV) has been
hampered by major difficulties that occurred in the 1960s when a formalin-inactivated …

Respiratory syncytial virus (RSV) disease is an important cause of morbidity and mortality in
children and debilitated adults and remains one of the major global unmet challenges for …